2026-01-07 東京大学
もの忘れが始まる段階で減少するドレブリン
<関連情報>
- https://www.a.u-tokyo.ac.jp/topics/topics_20260107-1.html
- https://journals.sagepub.com/doi/10.1177/13872877251404412
ドレブリンはアルツハイマー病における認知機能低下の新たなバイオマーカーである Drebrin is a novel biomarker of cognitive deterioration in Alzheimer’s disease
Mikio Shoji, Takeshi Kawarabayashi, […], and Tomoaki Shirao
Journal of Alzheimer’s Disease Published:January 2, 2026
DOI:https://doi.org/10.1177/13872877251404412
Abstract
Background
The cerebrospinal fluid (CSF) and plasma amyloid-β (Aβ)40/42 ratio, p-217tau and p-181tau, and neurofilament light chain are biomarkers of Aβ proteinopathy, tau proteinopathy, and neuronal injury, respectively, in Alzheimer’s disease (AD). However, direct biomarkers of cognitive function have yet to be identified.
Objective
Therefore, the present study investigated the potential of CSF and plasma levels of drebrin, a postsynaptic protein, as biomarkers of synaptic activity and cognitive function in the human brain in clinical settings.
Methods
We developed a novel ELISA to measure CSF and plasma levels of drebrin and analyzed 68 CSF and 128 plasma samples from patients with AD and other neurological diseases.
Results
CSF drebrin levels were significantly reduced in samples of mild cognitive impairment due to AD, the dementia stages of AD, and idiopathic normal pressure hydrocephalus. Plasma drebrin levels were also significantly reduced in samples of MCI due to AD.
Conclusions
CSF and plasma drebrin levels are specific biomarkers of cognitive decline in the MCI stage of AD.
